ライフサイエンスコーパス: contrast-enhanced

1 us, and connectivity of in vivo vessels from contrast-enhanced 3D Magnetic Resonance Angiography.

2 Contrast enhanced abdominal CT not only confirmed the en

3 Contrast-enhanced abdominal computed tomography showed m

4 Evaluation with a contrast-enhanced abdominopelvic computed tomography (CT

5 ffect on the results of quantitative dynamic contrast-enhanced analysis of breast tissue at 3 T, whic

6 ment patterns based on a protocol with a non-contrast-enhanced and two contrast-enhanced phases.

7 covery imaging sequences) and multiregional (contrast-enhanced and unenhanced) tumor volumes.

8 daries differed between T2-weighted, dynamic contrast-enhanced, and diffusion-weighted sequences (mea

9 ach versus a strictly T2-weighted or dynamic contrast-enhanced approach through an improvement in sen

10 t predominantly (in 4/5 patients) within MRI contrast-enhanced areas, although (89)Zr-bevacizumab upt

11 derwent 3D time-of-flight MR angiography and contrast-enhanced BB 3-T MR imaging for intracranial ath

12 le (FA) mapping were included in the dynamic contrast-enhanced breast MR imaging protocol with a 1.5-

13 hould be considered for quantitative dynamic contrast-enhanced breast MR imaging, even at 1.5 T, to o

14 y rehearsed the procedure step by step using contrast-enhanced cardiac computed tomography and a pati

15 cardial late gadolinium enhancement (LGE) on contrast-enhanced cardiac magnetic resonance (group A) w

16 ntricular late enhancement was identified by contrast-enhanced cardiac magnetic resonance in 93% of p

17 Contrast-enhanced cardiac magnetic resonance may help to

18 c left ventricular (LV) scar as evidenced by contrast-enhanced cardiac magnetic resonance remain to b

19 ythmias underwent a study protocol including contrast-enhanced cardiac magnetic resonance.

20 Contrast-enhanced cardiovascular magnetic resonance (CMR

21 admill test with blood lactate analysis, and contrast-enhanced cardiovascular magnetic resonance imag

22 nts underwent multimodal cardiac assessment: contrast-enhanced cardiovascular magnetic resonance, ech

23 with special focus on the right ventricle by contrast-enhanced cardiovascular magnetic resonance.

24 DG PET with CT-based attenuation correction, contrast-enhanced (ce) CT, and conventional diagnostic M

25 While blinded to the PET findings, contrast-enhanced computed tomographic angiography was p

26 ly practice as a better predictive tool than contrast-enhanced computed tomographic scan for therapeu

27 Radiogenomic venous invasion (RVI) is a contrast-enhanced computed tomography (CECT) biomarker o

28 Contrast-enhanced computed tomography (CT) and magnetic

29 ery of liver lesions at US led us to perform contrast-enhanced computed tomography (CT) of the chest,

30 Bladder schistosomiasis was suspected after contrast-enhanced computed tomography and later confirme

31 Contrast-enhanced Computed Tomography Angiography examin

32 Initial staging was done with contrast-enhanced computed tomography of the chest, abdo

33 l leisure sports underwent a noncontrast and contrast-enhanced computed tomography scan to assess cor

34 earance of the middle cerebral artery on non-contrast-enhanced computed tomography.

35 All patients who underwent contrast-enhanced (contrast material group) or unenhance

36 ontrast coronary artery calcium (CAC) CT and contrast-enhanced coronary CT angiography at baseline an

37 f preoperative imaging with USG, Doppler and contrast enhanced CT scan can provide correct diagnosis.

38 e the accuracy of combined (18)F-FDG PET and contrast-enhanced CT ((18)F-FDG PET/CT), multidetector C

39 y) with HL were prospectively evaluated with contrast-enhanced CT (CECT) and PET combined with low-do

40 y) with HL were prospectively evaluated with contrast-enhanced CT (CECT) and PET combined with low-do

41 Contrast-enhanced CT (CECT) using CA4+ reveals significa

42 ic contrast-enhanced MR imaging (DCEMRI) and contrast-enhanced CT (DCECT) for hepatocellular carcinom

43 Contrast-enhanced CT and MR venography were the most sen

44 2 or greater esophageal tumors who underwent contrast-enhanced CT before and after CRT between 2005 a

45 Patients were followed up with contrast-enhanced CT every 2-4 months.

46 cion of a thrombus, which was confirmed on a contrast-enhanced CT examination.

47 erial propagation can be applied to simulate contrast-enhanced CT examinations.

48 Visual- and density-based analysis on contrast-enhanced CT failed to differentiate affected fr

49 premedication regimen before low-osmolality contrast-enhanced CT for a prior allergic-like or unknow

50 Patients who underwent contrast-enhanced CT had an increased amount of DNA radi

51 ith corticosteroids beginning 5 hours before contrast-enhanced CT has a breakthrough reaction rate no

52 Conclusion Adding unenhanced CT to contrast-enhanced CT improved the sensitivity, diagnosti

53 e of AKI, dialysis, or death attributable to contrast-enhanced CT in patients with a solitary kidney

54 ents were upstaged by marrow biopsy and 7 by contrast-enhanced CT in the bowel and/or liver or spleen

55 ocedures, such as bone scanning and possibly contrast-enhanced CT of the thorax or abdomen-pelvis.

56 SPECT with coregistered contrast-enhanced CT or MR imaging and SPECT/CT images o

57 was to examine whether (18)F-FDG PET/CT and contrast-enhanced CT performed immediately after percuta

58 However, contrast-enhanced CT pulmonary angiography (CTPA) has sh

59 Long-term follow-up by way of a contrast-enhanced CT revealed no recanalization of the t

60 Contrast-enhanced CT revealed partial remission in 5, st

61 The abdominal contrast-enhanced CT scan evidenced acute lesions of the

62 2 MBq) of (64)Cu-DOTATATE after a diagnostic contrast-enhanced CT scan.

63 ure mass transport properties during routine contrast-enhanced CT scans of individual human PDAC tumo

64 (18)F-FDG PET/CT and contrast-enhanced CT scans were acquired every 3 mo.

65 h follow-up gadolinium-enhanced MR images or contrast-enhanced CT scans.

66 Contrast-enhanced CT serves as a useful imaging tool for

67 rospective assessments of 164 unenhanced and contrast-enhanced CT studies from 158 consecutive patien

68 A total of 20 contrast-enhanced CT volume scans were acquired in 5 swi

69 SPECT imaging quantification based on contrast-enhanced CT was reproducible (interexperimenter

70 cohort (n = 1425) of patients who underwent contrast-enhanced CT without premedication and who had s

71 luded in estimating the risk associated with contrast-enhanced CT, may still not fully characterize t

72 essment models, minimum density analysis and contrast enhanced-CT in the relative subgroups of nodule

73 Thus, contrast-enhanced CTPA superior over non-contrast_enhanc

74 Direct contrast enhanced (DCE) MRI revealed the homogenous dist

75 ptor (ER)-positive breast cancers on dynamic contrast enhanced (DCE)-MRI that are correlated with the

76 Dynamic Contrast Enhanced (DCE-)MRI can depict the tumor microen

77 minant pulse sequence and benefit of dynamic contrast-enhanced (DCE) imaging, odds ratios (ORs) were

78 Moreover, dynamic contrast-enhanced (DCE) MRI revealed significantly reduc

79 ygenation-level-dependent (TOLD) and dynamic contrast-enhanced (DCE)-MRI.

80 -4 cm underwent single-energy unenhanced and contrast-enhanced dual-energy computed tomography (CT) o

81 Conclusion A contrast-enhanced dual-energy CT protocol developed by u

82 Conclusion Contrast-enhanced dual-energy CT with material attenuati

83 47 adrenal nodules underwent nonenhanced and contrast-enhanced dual-energy multidetector CT of the ab

84 Contrast-enhanced dual-energy multidetector CT with mate

85 tistically significant decrease (of 4.6%) on contrast-enhanced DW images, compared to unenhanced imag

86 Contrast-enhanced ECG-gated PET-CT permitted localizatio

87 ygen to the anaemic fetal heart muscle using contrast-enhanced echocardiography.

88 ng surveillance US allows for prompt dynamic contrast-enhanced evaluation, removing the need for furt

89 2-weighted and DW images between the dynamic contrast-enhanced examination and hepatobiliary phase is

90 resolution at all points during the dynamic contrast-enhanced examination.

91 % CI: -0.25, 0.48; P = .49), or time between contrast-enhanced examinations (r = -0.06; 95% CI: -0.42

92 45 +/- 0.0110 for girls; P = .88), number of contrast-enhanced examinations (r = 0.13; 95% CI: -0.25,

93 constitutive activation of BR signaling, in contrast, enhanced freezing resistance.

94 age 6 wk after negative (18)F-FDG PET/CT (CT contrast-enhanced, full-dose) in 15 consecutive radioiod

95 s the clinical feasibility of self-gated non-contrast-enhanced functional lung (SENCEFUL) magnetic re

96 In contrast, enhanced glucose storage as glycogen (glycogen

97 Abdominal dynamic contrast-enhanced gradient-recalled echo MR sequence aft

98 enhanced images then and both unenhanced and contrast-enhanced images 1 month later.

99 The focal appearance of lesions on dynamic contrast-enhanced images may help discriminate atrophy a

100 ed bowel wall enhancement was evaluated with contrast-enhanced images then and both unenhanced and co

101 ancement with centripetal filling on delayed contrast-enhanced images.

102 hese methods enable high-quality noninvasive contrast-enhanced imaging of OCT in living subjects, inc

103 Higher T2-weighted, DW, and dynamic contrast-enhanced imaging PI-RADS scores were observed i

104 new single-wavelength photoacoustic dynamic contrast-enhanced imaging technique by employing a stimu

105 Contrast-enhanced imaging uncovered extrinsic compressio

106 entional with diffusion-weighted and dynamic contrast-enhanced imaging.

107 c resonance imaging and followed with serial contrast-enhanced imaging.

108 for diffusion-weighted, and 0.64 for dynamic contrast-enhanced imaging; 0.74 for the dominant paramet

109 Contrast-enhanced in vivo microCT enabled robust, noninv

110 (OR) for diagnostic success in patients with contrast-enhanced lesions was 2.54 ((1.25 to 5.15), p<0.

111 In contrast, enhanced lusitropy as a result of phosphorylat

112 yed post-contrast sequence in breast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) f

113 In this study, dynamic contrast-enhanced Magnetic Resonance Imaging (DCE-MRI) w

114 We apply CAM to dissect dynamic contrast-enhanced magnetic resonance imaging data taken

115 ious ultrasound findings in her left breast; contrast-enhanced magnetic resonance imaging showed regi

116 patients with malignant glial tumors, using contrast-enhanced magnetic resonance imaging to quantita

117 ndent magnetic resonance imaging and dynamic contrast-enhanced magnetic resonance imaging) and molecu

118 FDG positron emission tomography and dynamic contrast-enhanced magnetic resonance imaging, 46.9% (n=1

119 ndent magnetic resonance imaging and dynamic contrast-enhanced magnetic resonance imaging, pimonidazo

120 s assessed with mammography, ultrasound, and contrast-enhanced magnetic resonance imaging.

121 st that was depicted as an irregular mass on contrast-enhanced magnetic resonance imaging.

122 g included heavy T2-weighted MRI and dynamic contrast-enhanced magnetic resonance lymphangiogram.

123 Based on dynamic contrast-enhanced magnetic resonance lymphangiography an

124 udy had nontraumatic chylothorax and dynamic contrast-enhanced magnetic resonance lymphangiography wa

125 Here, using contrast enhanced micro-computed tomography, we present,

126 Equivalence of DCE dynamic contrast enhanced MR urography and RS renal scintigraphy

127 chniques, making substitution of DCE dynamic contrast enhanced MR urography for RS renal scintigraphy

128 dilated kidneys, equivalence of DCE dynamic contrast enhanced MR urography to RS renal scintigraphy

129 nt was underestimated by 4% when DCE dynamic contrast enhanced MR urography was used compared with th

130 Dynamic time-resolved contrast-enhanced MR angiography provides information re

131 Conclusion Mn-PyC3A enables contrast-enhanced MR angiography with comparable contras

132 gs of $1870 and $2068 versus noncontrast and contrast-enhanced MR cholangiopancreatography, respectiv

133 ereafter, the remaining full multiparametric contrast-enhanced MR images were read.

134 only a fraction of the full multiparametric contrast-enhanced MR images, consisting of single-plane

135 was similar to that of full multiparametric contrast-enhanced MR imaging (87.2%, 473 of 542).

136 -pentaacetic acid (Gd-EOB-DTPA) with dynamic contrast-enhanced MR imaging (DCEMRI) and contrast-enhan

137 Patients underwent dynamic contrast-enhanced MR imaging according to a standardized

138 Full multiparametric contrast-enhanced MR imaging allowed detection of one ad

139 el wall enhancement in the arterial phase at contrast-enhanced MR imaging and (b) parent or guardian

140 of biparametric versus full multiparametric contrast-enhanced MR imaging and between-reader agreemen

141 6 d, compared with 120 and 131 d for dynamic contrast-enhanced MR imaging and palpation, respectively

142 rwent state-of-the-art, full multiparametric contrast-enhanced MR imaging at 3.0-T including high-spa

143 larger scheduled for NACT underwent dynamic contrast-enhanced MR imaging before treatment (examinati

144 ral invasive breast cancer underwent dynamic contrast-enhanced MR imaging between 2000 and 2008.

145 Analysis of dynamic susceptibility contrast-enhanced MR imaging data by using principal com

146 Dynamic susceptibility contrast-enhanced MR imaging data were obtained for 79 p

147 e addition of diffusion-weighted and dynamic contrast-enhanced MR imaging for prediction of response

148 s of this meta-analysis suggest that dynamic contrast-enhanced MR imaging has moderate sensitivity an

149 This impacts the accuracy with which dynamic contrast-enhanced MR imaging helps predict complete path

150 Contrast-enhanced MR imaging of the abdomen was performe

151 el wall enhancement in the arterial phase at contrast-enhanced MR imaging over time (rho = -0.51, P =

152 o those of conventional full multiparametric contrast-enhanced MR imaging protocols.

153 ity-adjusted life-year [QALY] gained), while contrast-enhanced MR imaging was favored in younger adul

154 Contrast-enhanced MR imaging was favored with pretest pr

155 Before biopsy, full diagnostic contrast-enhanced MR imaging was performed that included

156 Image data from dynamic contrast-enhanced MR imaging were extracted and analyzed

157 Conclusion Parameter maps derived at dynamic contrast-enhanced MR imaging with high temporal resoluti

158 -weighted MR imaging, 0.41 and 0.57; dynamic contrast-enhanced MR imaging, 0.48 and 0.41; and overall

159 , 800, 1000, and 1400 mm(2)/sec, and dynamic contrast-enhanced MR imaging, obtained without endorecta

160 tumor detection using palpation and dynamic contrast-enhanced MR imaging.

161 MS patients with acute attack in addition to contrast-enhanced MR sequence.

162 atients with IIH who underwent brain MRI and contrast-enhanced MR venography before measurement of LO

163 radiological scores based on cranial MRI and contrast-enhanced MR venography in patients with idiopat

164 Dynamic contrast enhanced MRI (DCE-MRI) coupled with a pharmacok

165 ic performance of (68)Ga-DOTATATE PET/CT and contrast-enhanced MRI (CE-MRI) for the detection of osse

166 laque phenotype in RA patients using Dynamic Contrast-Enhanced MRI (DCE-MRI) and Fludeoxyglucose Posi

167 lung cancers (NSCLC), who underwent dynamic contrast-enhanced MRI (DCE-MRI) before concurrent chemo-

168 We used dynamic-contrast-enhanced MRI and kinetic modeling to quantify C

169 of Ran-SPION-rIgP/cIgY-MAP2 using molecular contrast-enhanced MRI in vivo and validated neuronal upt

170 Contrast-enhanced MRI is typically used to follow treatm

171 Contrast-enhanced MRI lymphography shows potential to id

172 A contrast-enhanced MRI method was developed in parallel t

173 nts underwent prone (18)F-FDG PET/CT and 3-T contrast-enhanced MRI of the breast.

174 for studies comparing CT with extracellular contrast-enhanced MRI or gadoxetate-enhanced MRI in adul

175 either gadoxetate-enhanced or extracellular contrast-enhanced MRI over CT.

176 Using an advanced dynamic contrast-enhanced MRI protocol with high spatial and tem

177 We conclude that chimera and molecular contrast-enhanced MRI provide sufficient sensitivity for

178 Molecular contrast-enhanced MRI results were confirmed by optical

179 oxygenation-level dependent MRI and dynamic contrast-enhanced MRI) did not relate to tumor hypoxia c

180 About one-third of these procedures are contrast-enhanced MRI, and gadolinium-based contrast age

181 he relative performance of CT, extracellular contrast-enhanced MRI, and gadoxetate-enhanced MRI for d

182 CT, extracellular contrast-enhanced MRI, or gadoxetate-enhanced MRI could

183 BB by low-intensity pFUS+MB, as evidenced by contrast-enhanced MRI, resulted in an immediate damage-a

184 rain barrier (BBB) was measured with dynamic contrast-enhanced MRI.

185 ng antiangiogenic therapy more reliably than contrast-enhanced MRI.

186 ariations of other abdominal arteries during contrast-enhanced multi-detector computed tomography (MD

187 lications of THV thrombosis as determined by contrast-enhanced multidetector computed tomography (MDC

188 gional measurements of signal attenuation at contrast-enhanced multidetector CT and counterstaining o

189 Contrast-enhanced multidetector CT is a suitable noninva

190 ullary perfusion and RBF were measured using contrast-enhanced multidetector CT, and renal oxygenatio

191 Unenhanced and contrast-enhanced nephrographic phase CT was performed.

192 Contrast-enhanced NIR optical imaging provides a sensiti

193 Quantitative analysis of contrast-enhanced optical imaging allows for potential t

194 thout B1 correction were seen in the dynamic contrast-enhanced parameters (including the volume trans

195 ssess semiquantitative parameters of dynamic contrast-enhanced perfusion MR imaging (DCE) in differen

196 [ITSS]), and dynamic susceptibility-weighted contrast-enhanced perfusion-weighted (relative cerebral

197 All patients underwent contrast-enhanced PET/CT after injection of 155 +/- 27 M

198 ern and thus could be missed without the non-contrast-enhanced phase.

199 most common and could be diagnosed with two contrast-enhanced phases.

200 rotocol with a non-contrast-enhanced and two contrast-enhanced phases.

201 ced images, but patterns differed in the two contrast-enhanced phases.

202 -breast images obtained in early and delayed contrast-enhanced phases.

203 A contrast-enhanced positron emission tomography (PET) wit

204 nanoparticle synthesis to SERRS nanoparticle contrast-enhanced preclinical Raman imaging in animal mo

205 included the development of a dual-energy CT contrast-enhanced protocol to evaluate peak arterial enh

206 ar type of gadolinium (gadodiamide) used for contrast-enhanced radiologic studies.

207 A maximal contrast-enhanced range of 25.5 HU could produce 78.8% s

208 ge, relative cerebral blood volume (rCBV) in contrast-enhanced regions (cutoff > 2.59; sensitivity, 8

209 ghted (before/after gadolinium), and dynamic contrast-enhanced scans were acquired at baseline and mo

210 In contrast, enhanced secreted and nuclear levels of the G5

211 Thin contrast- enhanced sections and multiplanar CT and MR sc

212 , PET/MR imaging with diffusion-weighted and contrast-enhanced sequences depicted distant (30 of 30 [

213 RI protocol consisted of both unenhanced and contrast-enhanced sequences.

214 Of those 52 patients, 46 were referred for contrast-enhanced spectral mammography and targeted ultr

215 These patients were referred for contrast-enhanced spectral mammography and targeted US a

216 In addition, contrast-enhanced spectral mammography depicted 11 of th

217 52 women who underwent breast MR imaging and contrast-enhanced spectral mammography for newly diagnos

218 Contrast-enhanced spectral mammography had similar sensi

219 Conclusion Contrast-enhanced spectral mammography is potentially as

220 Images from contrast-enhanced spectral mammography were analyzed by

221 st imagers with 2.5 years of experience with contrast-enhanced spectral mammography.

222 Contrast-enhanced steady state free precession (CE-SSFP)

223 Contrast-enhanced SWIFT imaging was completed by using a

224 ation zone on both T2-weighted (P = .01) and contrast-enhanced T1-weighted (P < .08) images.

225 ventricular volumes, ejection fraction, and contrast-enhanced T1-weighted and T2-weighted signal int

226 compare (18)F-FDG PET/MRI (performed using a contrast-enhanced T1-weighted fat-suppressed volume-inte

227 and 4 on T2-weighted images and kurtosis on contrast-enhanced T1-weighted images showed a significan

228 ventional (T1-weighted, fluid-sensitive, and contrast-enhanced T1-weighted imaging) and functional (D

229 ivariate model incorporating T2-weighted and contrast-enhanced T1-weighted kurtosis showed good perfo

230 tumors before disruption was evaluated using contrast-enhanced T1-weighted magnetic resonance imaging

231 Two observers independently evaluated contrast-enhanced T1-weighted MR images of superficial c

232 ardiovascular magnetic resonance measures of contrast-enhanced T1-weighted signal intensity occur com

233 ance (MR) imaging and dynamic susceptibility contrast-enhanced T2*-weighted perfusion MR imaging.

234 LSN scores from portal venous phase contrast-enhanced thick-section CT images had significan

235 m) that underwent echocardiography and gated contrast-enhanced thoracic aortic computed tomography or

236 proximal aorta >/=4 cm, who also had a gated contrast-enhanced thoracic computed tomography or magnet

237 erwent conventional MR imaging and a dynamic contrast-enhanced three-dimensional spoiled gradient-ech

238 Using synchrotron X-ray phase contrast-enhanced tomography we show exemplar data with

239 lastoma multiforme (GBM) with intraoperative contrast-enhanced ultrasonography (US) versus that with

240 icrobubbles, already clinically approved for contrast enhanced ultrasound imaging, in tissue engineer

241 Contrast-enhanced ultrasound (CEUS) is a recent non-inva

242 ith non-small cell lung cancer (NSCLC) using contrast-enhanced ultrasound (CEUS).

243 Dynamic contrast-enhanced ultrasound (DCEUS) and photoacoustic (

244 CBV in insulin resistance can be detected by contrast-enhanced ultrasound and correlates with the deg

245 erfusion and reduced hypoxia, as measured by contrast-enhanced ultrasound and photoacoustic imaging.

246 results illustrate the utility of a combined contrast-enhanced ultrasound method with photoacoustic i

247 Contrast-enhanced ultrasound molecular imaging can detec

248 We hypothesized that contrast-enhanced ultrasound molecular imaging could det

249 Contrast-enhanced ultrasound molecular imaging of the he

250 In contrast, contrast-enhanced ultrasound molecular imaging showed in

251 cular cell adhesion molecule-1 expression by contrast-enhanced ultrasound molecular imaging were asse

252 Contrast-enhanced ultrasound perfusion imaging of abdomi

253 Contrast-enhanced ultrasound revealed a heterogeneous pa

254 lar tool to address this limitation involves contrast-enhanced ultrasound using microbubbles targeted

255 nce of intraplaque neovascularization during contrast-enhanced ultrasound was judged semiquantitative

256 eased microvascular perfusion (determined by contrast-enhanced ultrasound) by 65% in the exercised le

257 Using contrast-enhanced ultrasound, we investigated whether ab

258 LBF by Doppler ultrasound and muscle MBV by contrast-enhanced ultrasound.

259 maging, glioblastoma contrast enhancement at contrast-enhanced US (regarding location, morphologic fe

260 Contrast-enhanced US also provides dynamic real-time ass

261 undergoing PCNL provided consent to undergo contrast-enhanced US and fluoroscopic nephrostograms on

262 ttern demonstrated a similar distribution in contrast-enhanced US and gadolinium-enhanced T1-weighted

263 ent, the terminal ileal loop was imaged with contrast-enhanced US before the beginning and at the end

264 These results demonstrate that contrast-enhanced US can help delineate the maximum area

265 Contrast-enhanced US demonstrated ureteral patency in ei

266 Contrast-enhanced US enhancement patterns were used to c

267 ndependently reviewed videotaped qualitative contrast-enhanced US examinations and were blinded to th

268 radiologist separately reviewed a subset of contrast-enhanced US examinations that were performed wi

269 is, 306 of 1018 (30.0%) were correlated with contrast-enhanced US findings: 167 (54.6%) were benign,

270 The application of contrast-enhanced US immediately following surveillance

271 Quantitative scrotal contrast-enhanced US is a noninvasive diagnostic tool th

272 Thus, contrast-enhanced US is of potential use in the surgical

273 usion Glioblastoma contrast enhancement with contrast-enhanced US is superimposable on that provided

274 Contrast-enhanced US may be a simple and accurate tool f

275 r studies confirm these preliminary results, contrast-enhanced US may provide a safer, more convenien

276 Conclusion Contrast-enhanced US nephrostograms are simple to perfor

277 o complications or adverse events related to contrast-enhanced US occurred.

278 All patients underwent contrast-enhanced US on the same one machine, and 68 pat

279 The authors believe contrast-enhanced US provides complementary information

280 Contrast-enhanced US results were compared against those

281 ual navigation enabled matching of real-time contrast-enhanced US scans to corresponding coplanar pre

282 were developed for cumulative unenhanced and contrast-enhanced US scores.

283 pattern differed between the two modalities: Contrast-enhanced US showed enhancement of the entire bu

284 Navigated contrast-enhanced US was performed after intravenous adm

285 dolinium-enhanced T1-weighted MR imaging and contrast-enhanced US was superimposable in all cases wit

286 Color Doppler US and contrast-enhanced US were performed to determine the abs

287 tients included 721 individuals referred for contrast-enhanced US with 1018 indeterminate renal masse

288 -rich angiomyolipomas, underwent qualitative contrast-enhanced US with a combination of three differe

289 For contrast-enhanced US, 1.5 mL of Optison (GE Healthcare,

290 ratio was 5.7 for color Doppler US, 4.3 for contrast-enhanced US, 3.6 for strain elastography, 14.3

291 By combining strain elastography and contrast-enhanced US, a sensitivity of 100% and specific

292 .4% for color Doppler US, 100% and 76.7% for contrast-enhanced US, and 100% and 72.1% for strain elas

293 For contrast-enhanced US, the rapidity of wash-in (34 of 44

294 d 14.3 for strain elastography combined with contrast-enhanced US.

295 subgroup of patients underwent quantitative contrast-enhanced US.

296 arity was present in all lesions (n = 94) at contrast-enhanced US.

297 ) lesions, which were positive for cancer at contrast-enhanced US.

298 h color Doppler US, strain elastography, and contrast-enhanced US.

299 nation) Dixon for attenuation correction and contrast-enhanced VIBE pulse sequences.

300 ignificantly improved by adding a diagnostic contrast-enhanced VIBE sequence to the PET/MR imaging pr